Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors

2002 ◽  
Vol 99 (4) ◽  
pp. 589-596 ◽  
Author(s):  
Katharina Schelwies ◽  
Isrid Sturm ◽  
Patricia Grabowski ◽  
Hans Scherübl ◽  
Isabell Schindler ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Colorectal Carcinoma ◽  
Protein Expression ◽  
Stage Iii ◽  
Uicc Stage ◽  
Bax Protein ◽  
Negative Prognostic Factor

Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis

2005 ◽  
Vol 21 (3) ◽  
pp. 221-230 ◽  
Author(s):  
Patricia Grabowski ◽  
Isrid Sturm ◽  
Katharina Schelwies ◽  
Kerstin Maaser ◽  
Heinz-Johannes Buhr ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Good Prognosis ◽  
Stage Iii ◽  
Uicc Stage

scholarly journals Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
A. Hallqvist ◽  
F. Enlund ◽  
C. Andersson ◽  
H. Sjögren ◽  
A. Hussein ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Induction Chemotherapy ◽  
Phase Ii Study ◽  
Stage Iii ◽  
Egfr Mutations ◽  
High Dose ◽  
Kras Mutations ◽  
Negative Prognostic Factor ◽  
Combined Radiochemotherapy ◽  
Independent Negative Prognostic Factor

Background. The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations. We wanted to explore the prognostic impact of mutated KRAS in the stage III setting treated with high-dose radiochemotherapy. Methods. Samples were obtained from patients participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where patients were treated with induction chemotherapy (carboplatin/paclitaxel) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy (cisplatin/docetaxel) followed by radiotherapy concurrent cetuximab. The samples were analysed regarding KRAS mutations, EGFR mutations, and EGFR FISH positivity. Results. Patients with mutated KRAS had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account. The prevalence of KRAS mutations, EGFR mutations, and EGFR FISH positivity were 28.8%, 7.5%, and 19.7%, respectively. Conclusion. Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy. The prevalence of KRAS mutations and EGFR mutations are as expected in this Scandinavian population.

scholarly journals Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6177
Author(s):  
Maxime Schmitt ◽  
Miguel Silva ◽  
Björn Konukiewitz ◽  
Corinna Lang ◽  
Katja Steiger ◽  
...  
Keyword(s):  
High Risk ◽  
Colorectal Carcinoma ◽  
Multivariate Analyses ◽  
Stage Iii ◽  
Uicc Stage ◽  
Prognostic Relevance ◽  
Risk Scenarios ◽  
Cdx2 Expression ◽  
Univariate Analyses ◽  
Sensitive Marker

Background: Special AT-rich sequence-binding protein 2 (SATB2) has emerged as an alternative immunohistochemical marker to CDX2 for colorectal differentiation. However, the distribution and prognostic relevance of SATB2 expression in colorectal carcinoma (CRC) have to be further elucidated. Methods: SATB2 expression was analysed in 1039 CRCs and correlated with clinicopathological and morphological factors, CDX2 expression as well as survival parameters within the overall cohort and in clinicopathological subgroups. Results: SATB2 loss was a strong prognosticator in univariate analyses of the overall cohort (p < 0.001 for all survival comparisons) and in numerous subcohorts including high-risk scenarios (UICC stage III/high tumour budding). SATB2 retained its prognostic relevance in multivariate analyses of these high-risk scenarios (e.g., UICC stage III: DSS: p = 0.007, HR: 1.95), but not in the overall cohort (DSS: p = 0.1, HR: 1.25). SATB2 loss was more frequent than CDX2 loss (22.2% vs. 10.2%, p < 0.001) and of higher prognostic relevance with only moderate overlap between SATB2/CDX2 expression groups. Conclusions: SATB2 loss is able to identify especially aggressive CRCs in high-risk subgroups. While SATB2 is the prognostically superior immunohistochemical parameter compared to CDX2 in univariate analyses, it appears to be the less sensitive marker for colorectal differentiation as it is lost more frequently.

Major prognostic impact of proapoptotic BAX protein expression in stage III (UICC) colon cancer treated by adjuvant chemotherapy

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9587-9587
Author(s):  
O. Nehls ◽  
T. Okech ◽  
C.-J. Hsieh ◽  
V. Gaco ◽  
H. G. Hass ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Protein Expression ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Bax Protein

scholarly journals Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck

2011 ◽  
Vol 104 (10) ◽  
pp. 1641-1648 ◽  
Author(s):  
T Bauernhofer ◽  
M Pichler ◽  
E Wieckowski ◽  
J Stanson ◽  
A Aigelsreiter ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Prolactin Receptor ◽  
Negative Prognostic Factor

Venous invasion as a prognostic factor in colorectal carcinoma

1997 ◽  
Vol 33 ◽  
pp. S163-S164
Author(s):  
M. Moutinho-Ribeiro ◽  
P. Ribeiro ◽  
M. Sobrinho-Simões
Keyword(s):  
Prognostic Factor ◽  
Colorectal Carcinoma ◽  
Venous Invasion

HLA-DR Antigen and Bax Protein Expression in Patients with Primary Non-Hodgkin's Gastric Lymphoma

2004 ◽  
Vol 23 (2) ◽  
pp. 87-92 ◽  
Author(s):  
A. Darom ◽  
I.P. Gomatos ◽  
E. Leandros ◽  
E. Chatzigianni ◽  
C. Fotiadis ◽  
...  
Keyword(s):  
Protein Expression ◽  
Gastric Lymphoma ◽  
Bax Protein ◽  
Hla Dr
Sign in / Sign up

Export Citation Format

Share Document